Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      May 26, 2023

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-designated Therapies for Oncology
    Bio Technology

    Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-designated Therapies for Oncology

    yourbiotechBy yourbiotechJanuary 29, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Flamingo Therapeutics, Inc., a biotechnology organization spearheading RNA-focusing on treatments in oncology, today declared that it has gone into a concurrence with Ionis Pharmaceuticals to foster RNA-designated treatments to treat different types of malignancy. This union is an extension of a current cooperation with Ionis on the FLAME™ disclosure motor, following Flamingo’s Series A financing in 2020.

    The understanding and revelation collusion will use Flamingo’s profound mastery in oncology and long non-coding RNAs (lncRNAs) in mix with Ionis’ aptitude in RNA-designated drug disclosure and improvement to propel applicants against targets considered undruggable with conventional methodologies. Flamingo’s pipeline will incorporate three clinical-stage programs from Ionis, inhibitors of STAT-3, Androgen Receptor (AR) and IRF4, and one preclinical-stage program that objectives MALAT1, an all around portrayed lncRNA target. Flamingo will likewise propel its restrictive revelation motor, FLAME (Flamingo LncRNA Antisense Mining Engine), that tends to lncRNAs, an enormous and undiscovered class of infection causing focuses inside the dim matter of the human genome.

    “We’re excited to fortify our relationship with Ionis who has been at the front line of RNA-designated treatment for a very long time,” said Michael Garrett, Chief Executive Officer of Flamingo. “We accept the blend of Ionis’ initiative in RNA and our state of the art lncRNA disclosure motor will grow the chances for applying RNA-designated ways to deal with oncology.

    Flamingo Therapeutics Expands Alliance with Ionis Pharmaceuticals to Develop RNA-designated Therapies for Oncology

     I would like to receive information from suppliers sponsoring this content and willing to share the information above with business book 25.SEND

    “We are satisfied that Flamingo is utilizing their center qualities in creating novel malignancy medications to progress inventive Ionis-found oncology treatments where there is a neglected need,” said Brett P. Monia, Ph.D., Ionis’ CEO.

    Regarding the collusion, Rob MacLeod, Ph.D., VP, Oncology Research and Development of Ionis, will fill in as Chief Scientific Officer of Flamingo. Under the conditions of the arrangement, Ionis is qualified to get achievement installments and eminences on future item deals of the STAT3, AR, IRF4 and MALAT1 programs. Flamingo holds full rights to its FLAME stage and all lncRNA programs outside of MALAT1.

    Flamingo Therapeutics was established by VIB, Ghent University, KU Leuven, the University of Michigan, Kurma Partners and PMV, in light of spearheading work drove by Professor Jean-Christophe Marine (VIB-KU Leuven), Professor Pieter Mestdagh (Ghent University) and Professor Arul Chinnaiyan (University of Michigan). These logical groups kicked off something new on non-coding RNA qualities in malignancy and were among quick to show a job for lncRNAs as sickness drivers in oncology.

    ABOUT FLAMINGO THERAPEUTICS

    Flamingo is spearheading RNA-designated treatments for oncology with cutting edge sciences. Flamingo has the most developed antisense RNA-focusing on oncology portfolio with three clinical projects focusing on undruggable record factors and join variations. To help and extend its pipeline, Flamingo has an exclusive revelation motor, FLAME™ (Flamingo LncRNA Antisense Mining Engine), that tends to lncRNAs, an enormous and undiscovered class of infection causing focuses inside the “dull matter” of the human genome. The Company was established in 2020 dependent on spearheading work in the field of lncRNAs in oncology with our scholarly accomplices at VIB, KU Leuven, Ghent University and the University of Michigan. Flamingo has a disclosure union with Ionis Pharmaceuticals and is upheld by notable biotechnology financial backers Kurma Partners and PMV. The organization is settled in Belgium with extra tasks in San Diego, CA.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleCRSwNP is often associated with asthma and allergic rhinitis but the cell and molecular mechanisms that make .
    Next Article GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
    yourbiotech
    • Website

    Related Posts

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.